Robeauté Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
16
Robeauté General Information
Description
Developer of a microrobotic medical platform designed to improve diagnosis, treatment, and monitoring of neurological diseases. The company offers minimally invasive microrobots that navigate brain tissue for targeted biopsies, drug delivery, and patient-specific data collection, enabling clinicians and surgeons to perform precise neurological procedures with improved accuracy and reduced tissue disruption.
Contact Information
Website
www.robeaute.comCorporate Office
- 29 rue du Faubourg
- Saint Jacques
- 75014 Paris
- France
Corporate Office
- 29 rue du Faubourg
- Saint Jacques
- 75014 Paris
- France
Robeauté Timeline
Robeauté Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Accelerator/Incubator | 09-Jun-2026 | Completed | Pre-Clinical Trials | |||
| 13. Later Stage VC | Completed | Pre-Clinical Trials | ||||
| 12. Later Stage VC (Series A) | 14-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 11. Accelerator/Incubator | 01-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 10. Accelerator/Incubator | 01-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 9. Accelerator/Incubator | 29-May-2024 | Completed | Pre-Clinical Trials | |||
| 8. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 7. Grant | 01-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 22-Jan-2022 | $3.26M | $4.52M | Completed | Pre-Clinical Trials | |
| 5. Accelerator/Incubator | 01-Jan-2022 | $1.26M | Completed | Pre-Clinical Trials |
Robeauté Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Shares | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Robeauté Patents
Robeauté Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026202068-A1 | Micro biopsy tool | Pending | 24-Mar-2025 | ||
| WO-2026139594-A1 | Microbot with tool platform forming a connection zone | Pending | 26-Dec-2024 | ||
| EP-4389051-A1 | Nose dive microrobot | Inactive | 22-Dec-2022 | ||
| EP-4637609-A1 | Nose dive microrobot | Pending | 22-Dec-2022 | ||
| US-20260215859-A1 | Nose dive microrobot | Pending | 22-Dec-2022 | A61B34/30 |
Robeauté Signals
Robeauté Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Google DeepMind | Corporation | |||
| Brainlab | PE-Backed Company | Minority | ||
| Cherry Ventures | Venture Capital | Minority | ||
| Kindred Ventures | Venture Capital | Minority | ||
| Phoenix Court | Venture Capital | Minority |
Robeauté FAQs
-
When was Robeauté founded?
Robeauté was founded in 2017.
-
Where is Robeauté headquartered?
Robeauté is headquartered in Paris, France.
-
What is the size of Robeauté?
Robeauté has 43 total employees.
-
What industry is Robeauté in?
Robeauté’s primary industry is Surgical Devices.
-
Is Robeauté a private or public company?
Robeauté is a Private company.
-
What is Robeauté’s current revenue?
The current revenue for Robeauté is .
-
How much funding has Robeauté raised over time?
Robeauté has raised $40.2M.
-
Who are Robeauté’s investors?
Google DeepMind, Brainlab, Cherry Ventures, Kindred Ventures, and Phoenix Court are 5 of 16 investors who have invested in Robeauté.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process